


CLEAR: **(Canadian LEadership on Antimicrobial Rea-life Usage) Registry**

FINAL Analysis of IV Dalbavancin Usage in Canada

IV Dalbavancin:


<https://rcsurvey.radyfhs.umanitoba.ca/surveys/?s=TPMWJX98HL>

CLEAR (n=160): IV Dalbavancin Reports by Province




CLEAR (n= 160): IV Dalbavancin

Age of Patients




CLEAR (n= 160): IV Dalbavancin Infections Treated



ABSSSI-acute bacterial skin and skin structure infection
BJI-bone and joint infection
#-device-related infection

CLEAR (n= 160): IV Dalbavancin Pathogen Treated

Directed therapy = 81.3%
Empiric therapy = 18.7%




Coryne* - Corynebacterium

CANADIAN ANTIMICROBIAL
RESISTANCE ALLIANCE




CLEAR (n= 160): IV Dalbavancin

Was Patient Bacteremic or in the ICU ?



CLEAR (n= 160): IV Dalbavancin

Why Was Dalbavancin Used ?



* Failure of previous antibiotics

[#] Convenience of single dose treatment


⁺ To facilitate hospital discharge

[&]AE-adverse effects/intolerance to other agents

^{\$}Resistance to other antibiotics

CLEAR (n= 160): IV Dalbavancin

Was IV Dalbavancin Susceptibility Testing Performed ?



Susceptibility method: Etest n=2; Disk diffusion n=5

CANADIAN ANTIMICROBIAL
RESISTANCE ALLIANCE



CLEAR (n= 160): IV Dalbavancin

How Was IV Dalbavancin Dosed / Infused ?

# (%) of Patients	IV Dalbavancin Dose
101 (63.1%)	1500 mg Single Dose
40 (25.0%)	1500 mg Day 1 and 1500 mg Day 8
5 (3.2%)	1500 mg Day 1 and 1000 mg 2 weeks later
4 (2.5%)	1000 mg Single Dose
3 (1.9%)	1000 mg Day 1 and 500 mg Day 8
2 (1.3%)	1500 mg Day 1 and 1000 mg 2 weeks later x 2
1 (0.6%)	1500 mg per week x 6 weeks
2 (1.3%)	1125 mg Single Dose
1 (0.6%)	500mg weekly x 6 months
1 (0.6%)	1500 mg Day 1 and 500 mg Day 8


Creatinine clearance measured in 100% (160/160) patients

Infusion time:


- short (15 min – 1 hour) 96.3% (154/160)
- Unknown 3.7% (6/160)

Dosing of Dalbavancin for **ABSSSI** (On-Label)

(CLEAR; n= 92)




Dosing of Dalbavancin for **BJI** (Off-Label) (CLEAR; n= 39)




(Also 1000mg day 1 then 500mg day 8 [n=1]; 1000mg day 1 then 500mg weekly x 2 [n=1]) Adapted from Zhanel et al. AMMI 2024.

Dosing of Dalbavancin for **Endocarditis** (Off-Label) (CLEAR; n= 10)



Adapted from Zhanel et al. AMMI 2024.

Dosing of Dalbavancin for **Bloodstream/Vascular** (Off-Label) (CLEAR; n= 17)




Adapted from Zhanel et al. AMMI 2024.

* 500mg weekly x 6 months

Dosing of Dalbavancin for Off-Label


(CLEAR; n= 2)



Adapted from Zhanet et al. AMMI 2024.


CLEAR (n= 160): IV Dalbavancin

Where Was IV Dalbavancin Therapy Initiated




CLEAR (n= 160): IV Dalbavancin

Was IV Dalbavancin Used Along With Another Antibiotic ?




- Amoxicillin; amoxicillin/clavulanate x 4; ceftriaxone; ciprofloxacin + metronidazole; ceftazidime + metronidazole
- Metronidazole x 2; TMP/SMX x 4; TMP/SMX + ceftriaxone; levofloxacin x 2, vancomycin; tobramycin; vancomycin + ceftriaxone; cefazolin

CLEAR (n= 160): IV Dalbavancin Duration of Treatment (# Doses)




Other – weekly for 6 months


CLEAR (n= 160): IV Dalbavancin Microbiological Outcome



CLEAR (n= 160): IV Dalbavancin Clinical Outcome



CLEAR (n= 160): IV Dalbavancin Adverse Effects



redness, itchiness on entire body

Conclusions – CLEAR IV Dalbavancin

1. Dalbavancin is used to treat mostly ABSSSI but also bone and joint, bloodstream/vascular, endocarditis and device-related infections
2. Dalbavancin is used both as directed therapy (MRSA, *Streptococcus* spp., MSSA, MRSE, mixed infection) as well as empiric therapy
3. Dalbavancin is used due to its convenient single dose therapy (eg. IVDU, homelessness, mental health, adherence concerns), to facilitate hospital discharge as well as failure of prior used antimicrobials
4. Dalbavancin is used mostly without antimicrobial susceptibility testing

Conclusions – CLEAR IV Dalbavancin

5. Dalbavancin is used alone for MRSA infections but at times combined with a *B*-lactam, TMP/SMX or metronidazole
6. The most common IV dosage administered is 1500 mg single dose but a 2 dose regimen is also commonly used (all with a short infusion- 15min-1hour)
7. Dalbavancin treatment is associated with high rates of microbiological and clinical success
8. Only 1 adverse events (hypersensitivity) were reported in the 160 patients treated

CLEAR: **(Canadian Leadership on Antimicrobial Rea-life Usage) Registry**

Become a CLEAR participant (ggzhanel@pcsinternet.ca)

The CLEAR registry is live, participants receive an email periodically (every 3-4 months) of the most current data as well as links to the **current** registry (eg. **CLEAR - IV Ceftobiprole ENDOCARDITIS, IV Meropenem/Vaborbactam and Pediatric IV Fosfomycin**) so that interested ID/MM physicians and ID/Antimicrobial Stewardship pharmacists can enter patient data (prospective or retrospective)

Ceftobiprole ENDOCARDITIS: <https://rcsurvey.radyfhs.umanitoba.ca/surveys/?s=JM8JJHLA8N3JDKWA>

IV Meropenem/Vaborbactam: <https://rcsurvey.radyfhs.umanitoba.ca/surveys/?s=3H4FJ7HA49MDYHY8>

PEDIATRIC IV fosfomycin...<https://rcsurvey.radyfhs.umanitoba.ca/surveys/?s=FYHJNY4CRLJFN8DL>